Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation

被引:22
|
作者
Balci, Kevser Gulcihan [1 ]
Balci, Mustafa Mucahit [1 ]
Canpolat, Ugur [1 ]
Sen, Fatih [1 ]
Akboga, Mehmet K. [1 ]
Suleymanoglu, Muhammed [1 ]
Kuyumcu, Serdar [1 ]
Maden, Orhan [1 ]
Selcuk, Hatice [1 ]
Selcuk, Mehmet Timur [1 ]
机构
[1] Turkiye Yuksek Ihtisas Res & Educ Hosp, Dept Cardiol, Ankara, Turkey
来源
ANATOLIAN JOURNAL OF CARDIOLOGY | 2016年 / 16卷 / 07期
关键词
atrial fibrillation; warfarin; apixaban; dabigatran; quality of life; anxiety; HOSPITAL ANXIETY; DEPRESSION; GUIDELINES; MANAGEMENT; VALIDITY; THERAPY; DISEASE; IMPACT;
D O I
10.5152/AnatolJCardiol.2015.6334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to compare health-related quality of life (HRQoL) measures between novel oral anticoagulants (NOACs) and warfarin-treated Turkish patients who had been started on oral anticoagulants (OACs) due to non-valvular atrial fibrillation (AF) and to determine the effects of OACs on patient's emotional status, anxiety and depression. Methods: A total of 182 patients older than 18 years with non-valvular AF and being treated with OACs for at least 6 months according to current AF guidelines who were admitted to outpatient clinics between July 2014 and January 2015 were included in this cross-sectional study. The exclusion criteria were receiving OACs for conditions other than non-valvular AF and being unable to answer the questionnaire. A questionnaire was administered to all participants to evaluate HRQoL, depression and anxiety. The mean differences between the groups were compared using Student's t-test; the Mann-Whitney U test was applied for comparisons of the medians. Results: The annual number of hospital admissions was significantly higher in the warfarin group (p<0.001), and all HRQoL scores were significantly lower and Hospital Anxiety and Depression Scale (HADS) score was higher in the warfarin group (p<0.001). History of any type of bleeding was significantly higher in the warfarin group (p<0.001). However, none of the patients had major bleeding. Among patients who experienced bleeding, all HRQoL scores were significantly lower and HADS score was significantly higher (p<0.001 and p=0.002, respectively). Conclusion: Warfarin-treated patients had higher levels of self-reported symptoms of depression and anxiety and compromised HRQoL when compared with NOAC-treated patients. The results may be explained by higher rates of bleeding episodes and higher number of hospital admissions, which may cause restrictions in life while on warfarin treatment.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 50 条
  • [1] COMPARISON OF BLEEDING AND TREATMENT PERSISTENCE AMONG NEW USERS OF NOVEL ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Lamberts, Morten
    Harboe, Louise
    Lefevre, Cinira
    Evans, David
    Gislason, Gunnar
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 887 - 887
  • [2] Effect and risk of novel oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation
    Kawada, Tomoyuki
    JOURNAL OF CARDIOLOGY, 2017, 70 (1-2) : 99 - 99
  • [3] Novel oral anticoagulants in non-valvular atrial fibrillation
    Potpara, Tatjana S.
    Lip, Gregory Y. H.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (02) : 115 - 129
  • [4] Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
    Birkinshaw, Alexander
    Fry, Christopher H.
    Fluck, David
    Sharma, Pankaj
    Han, Thang S.
    JRSM CARDIOVASCULAR DISEASE, 2020, 9
  • [5] Inappropriate Dosing of Oral Anticoagulants among Patients With Non-Valvular Atrial Fibrillation
    Shrestha, Sulena
    Baser, Onur
    Zhou, Xinxiang
    Kwong, W. J.
    STROKE, 2017, 48
  • [6] CLINICAL AND DEMOGRAPHICS CHARACTERISTICS OF NON-VALVULAR ATRIAL FIBRILLATION PATIENTS SWITCHING FROM WARFARIN TO NOVEL ORAL ANTICOAGULANTS
    Kachroo, S.
    Pan, X.
    Liu, L.
    Kawabata, H.
    Phatak, H.
    VALUE IN HEALTH, 2014, 17 (07) : A500 - A501
  • [7] Novel Anticoagulants for Non-valvular Atrial Fibrillation
    Xu, Bo
    Whitbourn, Robert
    HEART LUNG AND CIRCULATION, 2012, 21 (08): : 463 - 467
  • [8] Health-related quality of life among atrial fibrillation patients using warfarin therapy
    Radaideh, Khaldoon M.
    Matalqah, Laila M.
    EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH, 2018, 15 (01): : e12763 - 1
  • [9] Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy
    Lip, Gregory Y. H.
    Keshishian, Allison
    Kang, Amiee
    Dhamane, Amol D.
    Luo, Xuemei
    Klem, Christian
    Rosenblatt, Lisa
    Mardekian, Jack
    Jiang, Jenny
    Yuce, Huseyin
    Deitelzweig, Steven
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (05) : 405 - 414
  • [10] New oral anticoagulants in non-valvular atrial fibrillation
    Francia P.
    Adduci C.
    Santini D.
    Musumeci B.
    Tocci G.
    High Blood Pressure & Cardiovascular Prevention, 2013, 20 (2) : 53 - 60